{ "story_id": "6369f5a1b0393dda3d1f9c369d0a5f37", "desk": "drm3", "revision": 1, "published_at": "2026-09-02T06:49:23.000Z", "content_hash": "64fb98171db2d707c6d6fcf8210b481ace0cbd1f7ddae43bc4e678433a5c8cb1", "hash_basis": "sha256 over `headline\\ndek\\nprose`, plus `\\n` + the canonical citations JSON when any source is placed, plus `\\n#blog` for blogs", "basis": { "headline": "Novartis suspends eight autoimmune trials after three patient deaths", "dek": "Swiss pharma Novartis halted eight clinical trials following the death of three patients due to severe immune responses.", "prose": "Novartis suspended eight clinical trials for an experimental therapy targeting autoimmune and neurological disorders at the end of August after the death of three patients. [^1]\n\nAlteogen Inc. signed an option and licensing agreement with Novartis AG worth up to 4.4 trillion won (US$3.2 billion) to develop and commercialize subcutaneous formulations using its ALT-B4 technology. [^2]\n\nA Novartis spokesperson stated that the trials were suspended temporarily following the registration of severe immune responses in the three cases. [^3]\n\nNovartis is conducting a thorough review of the observed safety events. [^4]\n\nThe company identified the fatal immune response as a known safety risk in CAR-T therapies, which modify patient immune cells to recognize and destroy cancer cells. [^5]\n\nAlteogen will receive royalties on net sales after commercialization in addition to the upfront potential value. [^6]\n\nNovartis AG will have exclusive rights, through multiple options, to develop and commercialize SC formulations for multiple products using ALT-B4. [^7]\n\nA March 19, 2027 CHF110/CHF140 put spread of 4,000 contracts indicates institutional hedging, buying protection against a drop to CHF110 while selling CHF140 puts to offset cost. [^8]\n\nNovartis AG may experience increased price swings as these large options positions play out, especially as September and October expiries approach, potentially triggering a gamma squeeze if the stock moves sharply toward key strikes. [^9]\n\nThe largest single options trade was over 4,300 contracts of the September 18, 2026 CHF130 call, amounting to 4,334 contracts traded with open interest of 9,743. [^10]\n\nTotal options volume for Novartis AG rose to 26,086 contracts by 10:10 a.m., with puts at 13,209 and calls at 12,877. [^11]\n\nThe deal marks Alteogen's fourth ALT-B4 licensing agreement with a global pharmaceutical company this year. [^12]", "cited": "[{\"statement\":\"Novartis suspended eight clinical trials for an experimental therapy targeting autoimmune and neurological disorders at the end of August after the death of three patients.\",\"source\":\"elpaisvallenato.com\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T14:25:19.000Z\",\"publisher_count\":1,\"sources\":[\"elpaisvallenato.com\"]},{\"statement\":\"Alteogen Inc. signed an option and licensing agreement with Novartis AG worth up to 4.4 trillion won (US$3.2 billion) to develop and commercialize subcutaneous formulations using its ALT-B4 technology.\",\"source\":\"Yonhap News Agency\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-02T06:49:23.000Z\",\"publisher_count\":1,\"sources\":[\"Yonhap News Agency\"]},{\"statement\":\"A Novartis spokesperson stated that the trials were suspended temporarily following the registration of severe immune responses in the three cases.\",\"source\":\"elpaisvallenato.com\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T14:25:19.000Z\",\"publisher_count\":1,\"sources\":[\"elpaisvallenato.com\"]},{\"statement\":\"Novartis is conducting a thorough review of the observed safety events.\",\"source\":\"elpaisvallenato.com\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T14:25:19.000Z\",\"publisher_count\":1,\"sources\":[\"elpaisvallenato.com\"]},{\"statement\":\"The company identified the fatal immune response as a known safety risk in CAR-T therapies, which modify patient immune cells to recognize and destroy cancer cells.\",\"source\":\"elpaisvallenato.com\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T14:25:19.000Z\",\"publisher_count\":1,\"sources\":[\"elpaisvallenato.com\"]},{\"statement\":\"Alteogen will receive royalties on net sales after commercialization in addition to the upfront potential value.\",\"source\":\"Yonhap News Agency\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-02T06:49:23.000Z\",\"publisher_count\":1,\"sources\":[\"Yonhap News Agency\"]},{\"statement\":\"Novartis AG will have exclusive rights, through multiple options, to develop and commercialize SC formulations for multiple products using ALT-B4.\",\"source\":\"Yonhap News Agency\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-02T06:49:23.000Z\",\"publisher_count\":1,\"sources\":[\"Yonhap News Agency\"]},{\"statement\":\"A March 19, 2027 CHF110/CHF140 put spread of 4,000 contracts indicates institutional hedging, buying protection against a drop to CHF110 while selling CHF140 puts to offset cost.\",\"source\":\"Investing.com\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T14:29:06.000Z\",\"publisher_count\":1,\"sources\":[\"Investing.com\"]},{\"statement\":\"Novartis AG may experience increased price swings as these large options positions play out, especially as September and October expiries approach, potentially triggering a gamma squeeze if the stock moves sharply toward key strikes.\",\"source\":\"Investing.com\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T14:29:06.000Z\",\"publisher_count\":1,\"sources\":[\"Investing.com\"]},{\"statement\":\"The largest single options trade was over 4,300 contracts of the September 18, 2026 CHF130 call, amounting to 4,334 contracts traded with open interest of 9,743.\",\"source\":\"Investing.com\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T14:29:06.000Z\",\"publisher_count\":1,\"sources\":[\"Investing.com\"]},{\"statement\":\"Total options volume for Novartis AG rose to 26,086 contracts by 10:10 a.m., with puts at 13,209 and calls at 12,877.\",\"source\":\"Investing.com\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T14:29:06.000Z\",\"publisher_count\":1,\"sources\":[\"Investing.com\"]},{\"statement\":\"The deal marks Alteogen's fourth ALT-B4 licensing agreement with a global pharmaceutical company this year.\",\"source\":\"Yonhap News Agency\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-02T06:49:23.000Z\",\"publisher_count\":1,\"sources\":[\"Yonhap News Agency\"]}]", "kind": "news" }, "receipt_verify": "Ed25519 over the dot-joined string `slice_hash.cursor_from.cursor_to.view.view_version.row_count`; public_key and sig are base64url of the raw 32-byte key / 64-byte signature", "receipt": null, "receipt_note": "this revision predates receipt-keeping (before v0.37.0); the filed row lives in the record", "generation_chain": { "wire": { "stream": "fountain_news", "story_id": "dcdc1113197c709f7edd7fc8635d2de6", "thread_id": "85eafbeb9b7b51ceabfabe47e16f502c", "thread_label": "Novartis", "novelty": "UPDATE", "content_hash": "bd5b3bdcae038d9dd0f8c502d9f43cfded18c5d387c08f2050eb681515412cf3", "last_published_at": "2026-09-02T06:49:23.000Z", "read_receipt": { "slice_hash": "069682019ef400563585527bab6474e0dc4419c25869011c2b01ad23bb466b71", "cursor_from": "eyJ0cyI6IjIwMjYtMDktMDJUMDY6NDY6NTIuMDAwMDAwWiIsImlkIjoiMWFmYjlhNThjYWIzZjJmNGNkN2I3YTRiZmQ3Y2YwOGYiLCJ2IjoiMSJ9", "cursor_to": "eyJ0cyI6IjIwMjYtMDktMDJUMDc6NDg6NDkuMDAwMDAwWiIsImlkIjoiZTlkZTA0NWE4NTRkNDJhYzAwMTVhN2EzZGE3MWMzOGQiLCJ2IjoiMSJ9", "view": "v_fountain_news", "view_version": "1", "row_count": 100, "window_days": 3, "bytes_scanned": 12017721, "credits": 8, "price_per_100_rows": 8, "sig": "4e4uuUUMSWBJT7xlEq27xWcgwtqZLJGYaNOsJ3sslOlxq3IrRr9i1CJiktWIbaGtetaDL4BBDFSkjx7Z91KnAg", "public_key": "bMUigy8O0jOnBxQ4Sc-5lwhIZ8LQVAhxMbR7qESVuUE", "signer_path": "lakehouse/data-extract/v1", "alg": "Ed25519", "signed": true } }, "written_at": "2026-09-02T22:41:08.424Z" }, "cited_facts": [ { "statement": "Novartis suspended eight clinical trials for an experimental therapy targeting autoimmune and neurological disorders at the end of August after the death of three patients.", "source": "elpaisvallenato.com", "instrument": "News", "claim_key": null, "published_at": "2026-09-01T14:25:19.000Z", "publisher_count": 1, "sources": [ "elpaisvallenato.com" ] }, { "statement": "Alteogen Inc. signed an option and licensing agreement with Novartis AG worth up to 4.4 trillion won (US$3.2 billion) to develop and commercialize subcutaneous formulations using its ALT-B4 technology.", "source": "Yonhap News Agency", "instrument": "News", "claim_key": null, "published_at": "2026-09-02T06:49:23.000Z", "publisher_count": 1, "sources": [ "Yonhap News Agency" ] }, { "statement": "A Novartis spokesperson stated that the trials were suspended temporarily following the registration of severe immune responses in the three cases.", "source": "elpaisvallenato.com", "instrument": "News", "claim_key": null, "published_at": "2026-09-01T14:25:19.000Z", "publisher_count": 1, "sources": [ "elpaisvallenato.com" ] }, { "statement": "Novartis is conducting a thorough review of the observed safety events.", "source": "elpaisvallenato.com", "instrument": "News", "claim_key": null, "published_at": "2026-09-01T14:25:19.000Z", "publisher_count": 1, "sources": [ "elpaisvallenato.com" ] }, { "statement": "The company identified the fatal immune response as a known safety risk in CAR-T therapies, which modify patient immune cells to recognize and destroy cancer cells.", "source": "elpaisvallenato.com", "instrument": "News", "claim_key": null, "published_at": "2026-09-01T14:25:19.000Z", "publisher_count": 1, "sources": [ "elpaisvallenato.com" ] }, { "statement": "Alteogen will receive royalties on net sales after commercialization in addition to the upfront potential value.", "source": "Yonhap News Agency", "instrument": "News", "claim_key": null, "published_at": "2026-09-02T06:49:23.000Z", "publisher_count": 1, "sources": [ "Yonhap News Agency" ] }, { "statement": "Novartis AG will have exclusive rights, through multiple options, to develop and commercialize SC formulations for multiple products using ALT-B4.", "source": "Yonhap News Agency", "instrument": "News", "claim_key": null, "published_at": "2026-09-02T06:49:23.000Z", "publisher_count": 1, "sources": [ "Yonhap News Agency" ] }, { "statement": "A March 19, 2027 CHF110/CHF140 put spread of 4,000 contracts indicates institutional hedging, buying protection against a drop to CHF110 while selling CHF140 puts to offset cost.", "source": "Investing.com", "instrument": "News", "claim_key": null, "published_at": "2026-09-01T14:29:06.000Z", "publisher_count": 1, "sources": [ "Investing.com" ] }, { "statement": "Novartis AG may experience increased price swings as these large options positions play out, especially as September and October expiries approach, potentially triggering a gamma squeeze if the stock moves sharply toward key strikes.", "source": "Investing.com", "instrument": "News", "claim_key": null, "published_at": "2026-09-01T14:29:06.000Z", "publisher_count": 1, "sources": [ "Investing.com" ] }, { "statement": "The largest single options trade was over 4,300 contracts of the September 18, 2026 CHF130 call, amounting to 4,334 contracts traded with open interest of 9,743.", "source": "Investing.com", "instrument": "News", "claim_key": null, "published_at": "2026-09-01T14:29:06.000Z", "publisher_count": 1, "sources": [ "Investing.com" ] }, { "statement": "Total options volume for Novartis AG rose to 26,086 contracts by 10:10 a.m., with puts at 13,209 and calls at 12,877.", "source": "Investing.com", "instrument": "News", "claim_key": null, "published_at": "2026-09-01T14:29:06.000Z", "publisher_count": 1, "sources": [ "Investing.com" ] }, { "statement": "The deal marks Alteogen's fourth ALT-B4 licensing agreement with a global pharmaceutical company this year.", "source": "Yonhap News Agency", "instrument": "News", "claim_key": null, "published_at": "2026-09-02T06:49:23.000Z", "publisher_count": 1, "sources": [ "Yonhap News Agency" ] } ], "note": "A signature proves who filed this and that it has not changed since. It never makes a claim true." }